Firocoxib
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Firocoxib: Veterinary COX-2 Inhibitor — No Repurposing Prediction Available
One-Sentence Summary
Firocoxib (DrugBank DB09217) is a COX-2 selective NSAID approved for veterinary use (dogs and horses) for pain and inflammation management. The TxGNN model returned no predicted new indications for this compound, likely due to insufficient human drug data in the knowledge graph. With zero Danish marketing authorisations, critical data gaps in MOA and safety information, and no supporting evidence, a full repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Veterinary use — osteoarthritis and pain control in dogs (Previcox) and horses (Equioxx) |
| Predicted New Indication | No prediction generated by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — not even applicable; no prediction returned) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for Firocoxib. This is likely because the compound is classified as a veterinary drug and is absent from the human drug nodes in the TxGNN knowledge graph, which is trained primarily on human medicine data.
Mechanistic data (MOA) is currently unavailable in the Evidence Pack. Based on pharmacological class, Firocoxib belongs to the COX-2 selective NSAID family — the same class as celecoxib and etoricoxib — and exerts its effect by selectively inhibiting cyclooxygenase-2, thereby reducing prostaglandin synthesis and inflammation. In principle, COX-2 inhibition has been explored in human oncology (colorectal cancer chemoprevention) and chronic inflammatory diseases. However, translating a veterinary compound to human repurposing requires dedicated safety pharmacology and toxicology studies, which have not been identified.
Without a TxGNN prediction to anchor this evaluation, and without human clinical experience or MOA documentation in the current Evidence Pack, mechanistic rationale cannot be formally assessed at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Firocoxib holds no marketing authorisations in Denmark (neither national Laegemiddelstyrelsen authorisations nor centralised EMA authorisations). The compound is not approved for human use in any EU member state.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Note that the existing SmPC covers veterinary use only; human safety data would need to be generated de novo before any clinical development could proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: Firocoxib is a veterinary-only compound with no Danish marketing authorisation, no TxGNN-predicted human indication, and critical data gaps in both MOA documentation and human safety profiling. There is currently no evidence base to support a repurposing hypothesis for human medicine.
To proceed, the following is needed:
- TxGNN re-query: Confirm whether Firocoxib is present in the TxGNN knowledge graph as a drug node; if absent, consider adding it via DrugBank-to-KG mapping before re-running the prediction pipeline
- MOA documentation: Retrieve full mechanism of action from DrugBank API (remediation noted in DG002) to enable mechanistic plausibility analysis
- Human safety data: Conduct a systematic literature review for any human pharmacokinetic, toxicology, or off-label use reports
- Regulatory landscape review: Check EMA, FDA, and PMDA databases for any pending or historical human-use applications
- Indication hypothesis generation: If a human disease target is proposed, perform manual literature mining (PubMed, ICTRP) to assess whether a repurposing rationale can be constructed independent of TxGNN output
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.